IMMUWIN - A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT for intermediate stage HCC

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

15 Dec 2020 → ongoing

Decision date (initial)

2024-09-03

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

Yes

Funding sources

AstraZeneca

External identifiers

EU CT number

2024-513950-32-00

EudraCT number

2019-004597-26

ClinicalTrials.gov

NCT04522544

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy, Efficacy, Safety

To assess the anti-tumor activity of the combination of durvalumab and tremelimumab with either Y-90 SIRT or DEB-TACE by objective response rate (ORR) within 6 months in patients with multinodular or large, solitary HCC, not eligible for resection or local ablation and no prior systemic anti-cancer therapy.

Secondary objectives 4

1. To assess the efficacy of the combination of durvalumab and tremelimumab with either Y-90 SIRT or DEB-TACE by progression free survival (PFS) and overall survival (OS).
2. To assess safety of the combination treatments (AEs, impact on liver function, use of subsequent therapies).
3. To assess ORR as best overall response (BOR) during therapy.
4. To assess quality of life (QoL).

Conditions and MedDRA coding

Intermediate stage hepatocellular carcinoma (HCC)

Regulatory references

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 18

1. Capable of giving written informed consent and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
2. Age ≥ 18 years at time of study entry.
3. Body weight > 30 kg.
4. Multinodular or large, solitary HCC, not eligible for resection or local ablation.
5. Histologically confirmed diagnosis of HCC.
6. Scheduled to receive locoregional therapy as standard of care.
7. At least one measurable site of disease as defined by RECIST 1.1 criteria with spiral CT scan or MRI.
8. No prior systemic anti-cancer therapy.
9. Child-Pugh A.
10. Performance status (PS) ≤ 1 (ECOG scale).
11. Life expectancy of at least 12 weeks.
12. Adequate blood count, liver-enzymes, and renal function: Hemoglobin ≥ 9.0 g/dL, absolute neutrophil count ANC ≥1.5 x 109/L (> 1500 per mm3), platelets ≥ 75 x 109/L (>75,000 per mm3); Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN); AST (SGOT), ALT (SGPT) ≤ 2.5 x institutional ULN unless liver metastases are present, in which case it must be ≤5x ULN; International normalized ratio (INR) ≤ 1.25.
13. Albumin ≥ 31 g/L.
14. Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine clearance CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance.
15. Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial and must use at least 1 highly effective form of contraception if sexually active.
16. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving IMP and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational products (durvalumab and tremelimumab). Women who are not of childbearing potential (i.e. who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception).
17. If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, meets the following criteria: Patients with HBV or HCV infection should be monitored for viral levels during study participation; Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA should have HBV DNA < 100 IU/ml and should be managed per local treatment guidelines. Controlled (treated) hepatitis B subjects will be allowed if they started treatment at the time point of enrollment into the study by the latest and treatment is continued during study participation and for ≥ 6 months after end of study treatment; HCV patients with advanced HCC are mostly not treated for their HCV infection. However, patients treated for HCV are considered suitable for inclusion if antiviral therapy has been completed prior to first administration of study drug.
18. Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

Exclusion criteria 23

1. Diffuse HCC or presence of vascular invasion or extrahepatic spread with the following exception: Invasion of a segmental portal vein or hepatic veins.
2. Patients with advanced liver disease as defined below: liver cirrhosis with stage Child Pugh B and C.
3. Any contraindications for hepatic embolization procedures: Known hepatofugal blood flow; Known porto-systemic shunt; Impaired clotting test (platelet count < 70 x 109/L, INR > 1.25); Renal failure/insufficiency requiring hemo-or peritoneal dialysis; Known severe atheromatosis; Total thrombosis or total invasion of the main branch of the portal vein.
4. Locoregional therapies ongoing or completed < 4 weeks prior to the baseline scan.
5. History of cardiac disease: Congestive heart failure > New York Heart Association (NYHA) class 2; active coronary artery disease (CAD) (myocardial infarction ≥ 6 months prior to study entry is allowed); cardiac arrhythmias (Grade > 2 NCI-CTCAE Version 5.0) which are poorly controlled with anti-arrhythmic therapy or requiring pace maker; uncontrolled hypertension; clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug.
6. Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months prior to the first dose of study drug with the exception of thrombosis of a segmental portal vein.
7. Prior, systemic anti-cancer therapy, radiotherapy administered < 4 weeks prior to study entry, endocrine- or immunotherapy or use of other investigational agents.
8. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection); systemic corticosteroids at physiologic doses not to exceed <<10 mg/day>> of prednisone or its equivalent; steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
9. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
10. Major surgery within 4 weeks of starting the study and patients must have recovered from effects of major surgery.
11. Patients with second primary cancer, except adequately treated basal skin cancer or carcinoma in-situ of the cervix, unless curatively treated and disease-free for 3 years or longer.
12. Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the study.
13. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
14. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice).
15. History of allogenic organ transplantation.
16. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or compliance with the study protocol.
17. Symptomatic brain metastases. A scan to confirm the absence of brain metastases is required in the presence of corresponding symptoms.
18. Pregnant or breast-feeding women.
19. Immunocompromised patients, e.g. patients who are known to be serologically positive for human immunodeficiency virus (HIV).
20. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]). The following are exceptions to this criterion: Patients with vitiligo or alopecia; patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement; any chronic skin condition that does not require systemic therapy; patients without active disease in the last 5 years may be included but only after consultation with the study physician; patients with celiac disease controlled by diet alone.
21. Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product.
22. Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
23. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Objective response rate (ORR) [according to RECIST 1.1] after 6 months.

Secondary endpoints 7

1. PFS
2. OS
3. Safety (AEs, impact of liver function, use of subsequent therapies)
4. ORR as BOR during therapy
5. ORR within 6 months for patients who received single treatment of TACE/SIRT
6. ORR within 6 months for patients who received additional treatment of TACE/SIRT
7. QoL

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Sponsor organisation

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Address

Steinbacher Hohl 2-26, Praunheim Praunheim

City

Frankfurt Am Main

Postcode

60488

Country

Germany

Scientific contact point

Organisation

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact name

Clinical Trial Project Manager

Public contact point

Organisation

Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact name

Clinical Trial Project Manager

Third parties 1

Locations

1 EU/EEA country · 11 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 6 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

4 submissions — initial application plus substantial / non-substantial modifications